Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics [Internet]. 2012 Jan. 1 [cited 2024 May 14];67(3):283-7. Available from: https://www.revistas.usp.br/clinics/article/view/19668